Nasdaq · Healthcare
BIOGEN INC. (BIIB)
As-reported financials and recent SEC filings for BIOGEN INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$9.89B
Net income
$1.29B
Net margin
13.1%
Diluted EPS
$8.79
ROE
7.1%
P/E (TTM)
23.3×
Market cap
$31.89B
Debt / equity
0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Gross profit | $7.49B | $7.37B | $7.30B | $7.90B | $8.87B |
| Operating income | — | — | — | — | $2.84B |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| Diluted EPS | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →Go deeper on BIIB
Search BIOGEN INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.